 |
市場調査レポート
商品コード
971973
角膜内皮ジストロフィー市場：洞察、疫学、および市場予測（2030年まで）Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast - 2030 |
||||||
| 角膜内皮ジストロフィー市場：洞察、疫学、および市場予測（2030年まで） |
|
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 137 Pages
納期: 約10営業日
|
主要7ヶ国（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）における角膜内皮ジストロフィー（CED）の市場規模は、2017年に575万米ドルとなり、総有病件数は1704万6,314件でした。
当レポートは、世界の角膜内皮ジストロフィー市場について調査しており、疾患の概要や疫学、市場規模と動向、成長要因および課題、パイプライン分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。
DelveInsight's 'Corneal Endothelial Dystrophy (CED) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Corneal Endothelial Dystrophy (CED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy (CED) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Corneal Endothelial Dystrophy (CED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of your eye. There are more than 20 types, each with different symptoms, all-cause a buildup of foreign material in one or more layers of your cornea. Over time, your vision may become cloudy or blurry.
Corneal dystrophies may not cause symptoms (asymptomatic) in some individuals; in others, they may cause significant vision impairment. The age of onset and specific symptoms vary among the different forms of corneal dystrophy. The disorders have some similar characteristics; most forms of corneal dystrophy affect both eyes (bilateral), progress slowly, do not affect other areas of the body, which tend to run in families. Most forms are inherited as autosomal dominant traits; a few are inherited as autosomal recessive traits.
Corneal Endothelial Dystrophy or Fuchs' endothelial dystrophy is a non-inflammatory, sporadic, or autosomal-dominant dystrophy involving the endothelial layer of the cornea. With Fuchs' dystrophy, the cornea begins to swell, causing glare, halo, and reduced visual acuity. The damage to the cornea in Fuchs' endothelial dystrophy can be so severe as to cause corneal blindness. Fuchs endothelial dystrophy (FED) is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients. When inherited, the transmission is autosomal dominant. The corneal endothelium is a monolayer of cells that acts as the major pump to deturgesce the cornea and ensures clarity.
It covers the details of conventional and current medical therapies and diagnosis available in the Corneal Endothelial Dystrophy (CED) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Corneal Endothelial Dystrophy (CED) market report gives a thorough understanding of Corneal Endothelial Dystrophy (CED) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Corneal Endothelial Dystrophy (CED) symptoms of treatment algorithms and treatment guidelines for Corneal Endothelial Dystrophy (CED) symptoms in the US, Europe, and Japan.
The clinical diagnosis of the corneal dystrophies is based on the age of onset and the clinical appearance of the cornea on slit-lamp bio-microscopy. When corneal tissue is excised, it should be examined by light microscopy and TEM, as this can establish the precise diagnosis of many corneal dystrophies. The diagnosis of Fuchs' endothelial dystrophy is clinical; however, some diagnostic tests can be helpful. Pachymetry, or measurement of the central corneal thickness, helps follow a patient with Fuchs' dystrophy. Over time one will see increasing corneal thickness as the disease worsens. The corneal thickness also may help with risk/benefit analysis of any other surgery that may be necessary (such as cataract surgery). Endothelial cell counts can also be helpful when counseling patients as to how quickly their dystrophy may progress as well as how safe any other intraocular surgery might be. In even moderate Fuchs' dystrophy, the cell count can be challenging to obtain. Evaluation of the endothelium by specular microscopy can demonstrate classic changes of Fuchs' endothelial dystrophy, including guttata, variation in cell size and shape, and low cell count per unit area.
For several decades, penetrating keratoplasty has been the only definitive treatment option for FECD. However, the development of minimally invasive lamellar endothelial keratoplasty (EK) procedures has provided key benefits such as better and faster visual recovery, a tectonically stronger globe, decreased risk of bleeding and infection, less astigmatism, less corneal denervation, and lower rejection rates. Newer modalities such as Descemetorhexis without endothelial keratoplasty (DWEK), endothelial cell injection, and nonsurgical approaches may offer options for further minimizing surgical risks and intervening before the onset of symptoms.
The Corneal Endothelial Dystrophy (CED) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The prevalent cases of Corneal Endothelial Dystrophy (CED) are increasing in 7MM during the study period, i.e., 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Corneal Endothelial Dystrophy (CED) symptoms epidemiology segmented as the Total Prevalent cases of Corneal Endothelial Dystrophy (CED), Gender-specific cases of Corneal Endothelial Dystrophy (CED), Age-Specific cases of Corneal Endothelial Dystrophy (CED), and Type-Specific cases of Corneal Endothelial Dystrophy (CED). The report includes the prevalent scenario of Corneal Endothelial Dystrophy (CED) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Corneal Endothelial Dystrophy (CED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Corneal Endothelial Dystrophy (CED) associated in 7MM countries was 17,046,314 in 2017.
The drug chapter segment of the Corneal Endothelial Dystrophy (CED) report encloses the detailed analysis of Corneal Endothelial Dystrophy (CED) early-stage (Phase-I/II, and II) pipeline drugs, and marketed drugs. It also helps understand the Corneal Endothelial Dystrophy (CED) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor that is supplied as a solution for ophthalmic administration. It possesses three different mechanisms of action in a single agent. The drug lowers the resistance to outflow through the trabecular meshwork and also decreases the production of fluid and episcleral venous pressure. Furthermore, Rhopressa also works at the cellular level within the trabecular network with a novel mechanism of action. The mechanism works by decreasing actin-myosin contraction and reducing actin stress fibers and focal adhesions in the trabecular meshwork to improve the outflow of aqueous humor.
The Corneal Endothelial Dystrophy (CED) market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy (CED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.
This segment gives a thorough detail of Corneal Endothelial Dystrophy (CED) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Corneal Endothelial Dystrophy (CED) market in 7MM is expected to grow in the study period 2017-2030.
Medical management of early Fuchs dystrophy consists of topical hypertonic saline drops or ointment to shorten morning edema. Patients may use the ointment at bedtime and/or the drops upon awakening, typically one drop every 5 min for a total of 3-4 drops; however, this treatment does not change the course of the disease. Patients do note stinging with these agents, which reduces acceptance. Also, a hairdryer held 5-10 inches from the cornea may be used to facilitate corneal deturgescence. As the disease progresses, these interventions will no longer be effective. Once patients are symptomatic from their FECD, surgery is the preferred treatment. Surgical management of endothelial dysfunction has undergone a revolution in the past 20 years. The only medical therapy that has been used to treat Fuchs dystrophy is as an adjuvant to surgical intervention.
Rhopressa (netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals, is also a Rho kinase inhibitor that is supplied as a solution for ophthalmic administration. The drug lowers the resistance to outflow through the trabecular meshwork and also decreases the production of fluid and episcleral venous pressure. It is used as an off-label usage for the treatment of FECD and is approved for the treatment of glaucoma.
This section includes a glimpse of the Corneal Endothelial Dystrophy (CED) market in 7MM. The market size of Corneal Endothelial Dystrophy (CED) in the seven major markets was found to be USD 5.75 Million in 2017.
This section provides the total Corneal Endothelial Dystrophy (CED) market size and market size by therapies in the United States.
The United States accounts for the largest market size of Corneal Endothelial Dystrophy (CED) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The total Corneal Endothelial Dystrophy (CED) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Corneal Endothelial Dystrophy (CED) market Size and market Size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Corneal Endothelial Dystrophy (CED) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I/II, and II stage. It also analyses Corneal Endothelial Dystrophy (CED) key players involved in developing targeted therapeutics.
Major players include Trefoil Therapeutics and Kowa Pharmaceuticals.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Corneal Endothelial Dystrophy (CED) emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Descemet's stripping endothelial keratoplasty (DSEK) or deep lamellar endothelial keratoplasty (DLEK) are new forms of keratoplasty. The term keratoplasty has always been a general term relating to surgery on the cornea, usually referring to a corneal graft procedure. Many cornea specialists are embracing these new procedures due to a shorter postoperative recovery for the patient when compared to traditional penetrating keratoplasty. The procedure involves a small incision in the cornea through which the surgeon strips away diseased or opacified endothelial corneal cells. Following stripping, harvested endothelium from a donor cornea is placed on the inner surface of the recipient cornea. The patient's compromised cornea clears rapidly once the new endothelium begins to function, and the common postoperative problems of penetrating keratoplasty related to sutures and astigmatism are avoided. DSEK or DLEK are not considered appropriate for all corneal pathologies; rather they are indicated for corneas with endothelial dysfunction.
To keep up with current market trends, we take KOLs and SME's opinion working in Corneal Endothelial Dystrophy (CED) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Corneal Endothelial Dystrophy (CED) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Corneal Endothelial Dystrophy (CED) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
比較リスト
